[BCG in superficial carcinoma of the bladder. Authors' experience].
Contribution of 95 patients with surface vesical tumour managed with UTR and endovesical BCG. The response was absence of recurrence in 68.4% cases in Ta stage, 63% in T1 and 66.7% in 'in situ' carcinoma. Therapy tolerability was good, with few side-effects. We conclude that BCG endovesical instillation as co-adjunctive therapy to UTR in surface vesical tumours has been shown to be effective for the period under study.
Bordalba Gómez
J R
JR
Servicio de Urología, Hospital de Bellvitge, Ciudad Sanitaria Princeps d'Espanya, Barcelona.
Muñoz Segui
J
J
Aguilo
F
F
Gil Vernet
A
A
Vigues
F
F
Lopez Costea
M A
MA
Serrallach
N
N
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000517:prevention & control; D009367:Neoplasm Staging; D011468:Prostatectomy; D013852:Thiotepa / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D001500:BCG Vaccine; D013852:Thiotepa
BCG en el carcinoma vesical superficial. Nuestra experiencia.